Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDII3NQOY7)
  Drug Name Quinestrol Drug Info Conestat alfa Drug Info
  Drug Type Small molecule Protein/peptide
  Therapeutic Class Antineoplastics Hereditary Angioedema Agents

 Mechanism of Quinestrol-Conestat alfa Interaction (Severity Level: Moderate)
     Additive thrombogenic effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Quinestrol Conestat alfa
      Mechanism Thrombogenic effects Thrombogenic effects
      Key Mechanism Factor 1
Factor Name Thrombogenic effects
Factor Description Drug-induced thrombosis disrupts the balance between thrombogenic factors and protective mechanisms and tends to produce thrombosis. Drug-induced thrombosis usually causes venous thrombotic events, and arterial thrombotic events are also noted as a result of drug administration
      Mechanism Description
  • Additive thrombogenic effects by the combination of Quinestrol and Conestat alfa 

Recommended Action
      Management Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain shortness of breath rapid pulse pain, swelling, and/or discoloration in an arm or leg and numbness or weakness on one side of the body.

References
1 Product Information. Berinert (complement C1 esterase inhibitor). CSL Behring, King of Prussia, PA.
2 Product Information. Cinryze (complement C1 esterase inhibitor). ViroPharma Incorporated, Exton, PA.
3 Product Information. Ruconest (conestat alfa). Valeant Pharmaceuticals, Costa Mesa, CA.
4 Gandhi PK, Gentry WM, Bottorff MB "Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database." Pharmacotherapy 32 (2012): 902-9. [PMID: 23033229]